Pan-PDK degrader-1
Pan-PDK degrader-1 is a pan-PDK class PROTAC degrader that degrades PDK2, PDK3 and PDK4 with DC50 values of 9.2 nM, 9.9 nM and 11.5 nM, respectively. Pan-PDK degrader-1 recruits the mitochondrial protease HsClpP and induces selective pan-PDK degradation via HsClpP-mediated proteolysis. Pan-PDK degrader-1 reprograms mitochondrial metabolism toward oxidative phosphorylation, promoting ROS accumulation, mitochondrial permeability transition pore opening, endogenous mitochondrial apoptosis, calreticulin exposure and HMGB1 release. Pan-PDK degrader-1 upregulates cleaved Caspase-9, Caspase-3 and PARP. Pan-PDK degrader-1 inhibits primary and distal tumor growth via selective degradation of PDK in tumor tissues. Pan-PDK degrader-1 can be used for the research of breast cancer.
(Pink: PDK2 and PDK3 and PDK4 ligand (HY-184945); Blue: HsClpP ligand (HY-184944); Black: linker).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C45H43ClF3N7O8S
- Peso molecular:934.38
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas PROTACs
MoreVer todos los productos específicos de isoformas Caspase
More
Actividad biológica
|
PDK2 9.2 nM (DC50) |
PDK3 9.9 nM (DC50) |
PDK4 11.5 nM (DC50) |
Caspase-9 |
Caspase-3 |
Pan-PDK degrader-1 (Compound A1) (0-1000 nM; 24 h) potently and selectively degrades PDK1-GFP in MCF-7 PDK1-GFP cells, with a DC50 of 94.6 nM, without altering mitochondrial protein homeostasis[1].
Pan-PDK degrader-1 (1-100 nM; 24 h) potently degrades endogenous PDK1 in MCF-7, HeLa, A549 and PANC-1 cancer cells, with DC50 values ranging from 8.3 to 97.0 nM, but exhibits only very low activity in cancer cell lines with low HsClpP expression and normal cell lines[1].
Pan-PDK degrader-1 (1-1000 nM; 24 h) is a potent pan-PDK degrader in MCF-7 cells. It degrades PDK2, PDK3 and PDK4 via a post-translational mechanism, with DC50 values of 9.2 nM, 9.9 nM and 11.5 nM, respectively, and does not alter the mRNA level of PDK1[1].
Pan-PDK degrader-1 (50-200 nM; 24 h)-induced PDK1 degradation in MCF-7 cells strictly depends on HsClpP, as knockdown or inhibition of HsClpP activity abolishes this effect, while competitive binding to PDK1 or HsClpP interferes with the degradation process[1].
Pan-PDK degrader-1 (100 nM-10 μM; 24 h) induces PDK1 degradation in MCF-7 cells independent of the ubiquitin-proteasome system and autophagy-lysosome pathway, relying solely on HsClpP-mediated proteolysis[1].
Pan-PDK degrader-1 (1-5 μM; 4-12 h) reprograms the metabolism of MCF-7 cells by inhibiting glycolysis and enhancing oxidative phosphorylation at relatively low concentrations, thereby reducing lactate production[1].
Pan-PDK degrader-1 (1-5 μM; 4 h) induces concentration-dependent accumulation of total ROS, intracellular superoxide, and mitochondrial superoxide in MCF-7 cells, and this effect is inhibited by antioxidant treatment[1].
Pan-PDK degrader-1 (1-5 μM; 4-6 h) selectively induces loss of mitochondrial membrane potential (MMP), opening of mitochondrial permeability transition pore (mPTP) and cytochrome c release in MCF-7 cancer cells, but exerts no such effects in normal Beas-2B or HS-5 cells, thereby triggering mitochondrial dysfunction[1].
Pan-PDK degrader-1 (50 nM-5 μM; 24-72 h) potently inhibits the proliferation of MCF-7 and MCF-7 PDK1-GFP cells and induces endogenous mitochondrial apoptosis in these cells. Its activity depends on the expression of HsClpP, while it exhibits extremely low toxicity toward normal cells[1].
Pan-PDK degrader-1 (1-10 μM; 6 h) induces typical immunogenic cell death (ICD) events in MCF-7 PDK1-GFP cells, including concentration-dependent cell surface exposure of CRT, HMGB1 release, and increased extracellular ATP levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 PDK1-GFP stable human breast cancer cells
-
Concentration:0, 1, 10, 50, 100, 1000 nM
-
Incubation Time:24 h
-
Result:Induced dose-dependent reduction of PDK1-GFP protein levels, with a DC50 of 94.6 nM.
Left HSP60 expression unchanged.
Showed a dose-dependent decrease in PDK1-GFP signal via confocal fluorescence imaging, confirming reduced PDK1-GFP protein levels.
-
Cell Line:wild-type human cancer cell lines (MCF-7, HeLa, A549, PANC-1, MIAPaCa-2, HT1080), normal cell lines (HUVEC, HS-5, Beas-2B)
-
Concentration:1, 10, 50, 75, 100 nM
-
Incubation Time:24 h
-
Result:Induced dose-dependent PDK1 degradation in a cell context-dependent manner: MCF-7 cells showed a DC50 of 8.3 nM, HeLa cells showed a DC50 of 9.9 nM, A549 cells showed a DC50 of 80.6 nM, and PANC-1 cells showed a DC50 of 97.0 nM.
Left MIAPaCa-2, HT1080, and normal cell lines (HUVEC, HS-5, Beas-2B) with DC50 values exceeding 100 nM, with minimal to no PDK1 degradation observed.
Left HSP60 expression unchanged across all cell lines.
-
Cell Line:wild-type MCF-7 human breast cancer cells
-
Concentration:1, 10, 50, 75, 100 nM
-
Incubation Time:24 h
-
Result:Induced dose-dependent degradation of PDK2, PDK3, and PDK4, with DC50 values of 9.2 nM, 9.9 nM, and 11.5 nM, respectively.
Left HSP60 expression unchanged.
-
Cell Line:MCF-7 (wild-type, PDK1-GFP-overexpressing, HsClpP-knockdown) human breast cancer cells, normal cell lines (HS-5, Beas-2B)
-
Concentration:50, 100, 200, 500 nM
-
Incubation Time:72 h
-
Result:Inhibited proliferation of MCF-7 cells (IC50 = 6.12 μM) and MCF-7 PDK1-GFP cells (IC50 = 3.3 μM), but showed minimal activity in MCF-7 shClpP cells (IC50 > 20 μM) and normal cells.
Suppressed colony formation in MCF-7 PDK1-GFP cells in a dose-dependent manner, but had little effect in HsClpP-knockdown cells.
-
Cell Line:MCF-7 (wild-type, PDK1-GFP-overexpressing, HsClpP-knockdown) human breast cancer cells, normal cell lines (HS-5, Beas-2B)
-
Concentration:1, 2, 5 μM
-
Incubation Time:24 h
-
Result:Induced concentration- and time-dependent apoptosis.
Increased levels of cleaved Caspase-9, cleaved Caspase-3, and cleaved PARP, while Caspase-8 levels remained unchanged.
Pan-PDK degrader-1 (10-20 mg/kg; intratracheal administration; administered on days 6, 9 and 12) induces the production of immunogenic cell death markers and inhibits the polarization of immunosuppressive macrophages, thereby suppressing the growth of primary and distal breast tumors in immunocompetent BALB/c mice with good tolerability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 5-6 weeks old)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.t.; every 2 days; 14 days
-
Result:Significantly reduced tumor volumes and weights relative to vehicle control.
Markedly reduced PDK1, PDK2, PDK3, and PDK4 protein levels in tumor tissues, with no change in mitochondrial marker HSP60.
Decreased phosphorylation of PDH at Ser293.
Elevated levels of cleaved Caspase-3 and cleaved Caspase-9.
Reduced tumor cell density, cytoplasmic shrinkage, and stromal edema in treated tumors, with no histopathological changes in major organs.
Caused no significant body weight changes during treatment.
-
Animal Model:BALB/c (female, immunocompetent)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.t.; on days 6, 9, 12
-
Result:Significantly reduced the volumes and weights of both primary and distant tumors relative to vehicle control.
Induced dose-dependent increases in calreticulin (CRT) exposure and HMGB1 release in tumor tissues.
Reduced expression of M2 macrophage markers MRC-1 and Arg-1 in both primary and distant tumors.
Caused no significant body weight changes during treatment.
Chemical Information
-
Peso molecular 934.38
-
Fòrmula C45H43ClF3N7O8S
-
SMILES
O=C(C1=CC=C(C=C1)S(=O)(C2=CC=C(C(Cl)=C2)NC([C@@](O)(C(F)(F)F)C)=O)=O)NCCOCCOC3=C(C=CC=C3)CN4C5=NCCN5C6=C(C4=O)CN(CC6)CC7=CC=CC(C#N)=C7
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)